Literature DB >> 21822918

Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma.

B Amend1, J Hennenlotter, M Scharpf, S Kruck, U Kuehs, E Senger, A S Merseburger, M A Kuczyk, K D Sievert, A Stenzl, J Bedke.   

Abstract

PURPOSE: Renal oncocytomas are assigned as benign tumours, and their detailed molecular mechanism is poorly characterised. Activation of the PKB/Akt pathway is assumed to contribute to the pathogenesis and progression of malignant disease. For oncocytomas, hardly any data are available for Akt signalling parameters. Aim of the present work was to determine the alterations of Akt parameters PTEN, phosphorylated Akt (p-Akt) and p27(Kip1) in oncocytoma to better understand the dedifferentiation of renal tumours.
METHODS: By tissue microarray analysis 15 oncocytoma, 18 clear cell renal cell carcinoma (ccRCC) and the corresponding benign tissue were investigated. Significant expression differences between PTEN, p-Akt and p27(Kip1) were determined by immunohistochemistry using One-way ANOVA with all pairs Tukey-Kramer as post hoc analyses. To investigate Akt parameter interactions in the oncocytoma, linear regression analyses were performed.
RESULTS: Expression of all proteins was significantly different between the groups and in all groups the lowest for oncocytoma: PTEN: 32.9 ± 13.0 versus 75.5 ± 8.0 versus 123.7 ± 8.8; p < 0.001 for oncocytoma, benign parenchyma and ccRCC and 2.7 ± 1.2 versus 40.8 ± 9.5 versus 143.6 ± 12.2; p < 0.001 for p27(Kip1). p-Akt expression was significantly different between oncocytoma and ccRCC (67.3 ± 15.7 vs. 144.0 ± 26.6; p < 0.05).
CONCLUSION: All three investigated parameters were the lowest in oncocytoma when compared to ccRCC. Expression of PTEN and p27(Kip1) seems to be exceedingly associated with malignant conditions of ccRCC. These findings might contribute to the understanding of tumorous signalling of the PKB/Akt axis in renal tumours.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822918     DOI: 10.1007/s00345-011-0737-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  27 in total

Review 1.  The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.

Authors:  F Vazquez; W R Sellers
Journal:  Biochim Biophys Acta       Date:  2000-02-14

Review 2.  Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm?

Authors:  Th Van der Kwast; B Perez-Ordoñez
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.

Authors:  Stephen Rohan; Jiangling J Tu; Jean Kao; Piali Mukherjee; Fabien Campagne; Xi K Zhou; Elizabeth Hyjek; Miguel A Alonso; Yao-Tseng Chen
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

6.  Renal oncocytoma: a clinicopathological analysis of 45 consecutive cases.

Authors:  Tomas Gudbjartsson; Sverrir Hardarson; Vigdis Petursdottir; Asgeir Thoroddsen; Jonas Magnusson; Gudmundur V Einarsson
Journal:  BJU Int       Date:  2005-12       Impact factor: 5.588

Review 7.  Oncogenic PI3K and its role in cancer.

Authors:  Yardena Samuels; Kajsa Ericson
Journal:  Curr Opin Oncol       Date:  2006-01       Impact factor: 3.645

Review 8.  Regulation of the cdk inhibitor p27 and its deregulation in cancer.

Authors:  J Slingerland; M Pagano
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

9.  Frequency, clinical presentation and evolution of renal oncocytomas: multicentric experience from a European database.

Authors:  Leo Romis; Luca Cindolo; Jean Jacques Patard; Giovanni Messina; Vincenzo Altieri; Laurent Salomon; Claude Clement Abbou; Dominique Chopin; Bernard Lobel; Alexandre de La Taille
Journal:  Eur Urol       Date:  2004-01       Impact factor: 20.096

Review 10.  Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms.

Authors:  Liang Cheng; Shaobo Zhang; Gregory T MacLennan; Antonio Lopez-Beltran; Rodolfo Montironi
Journal:  Hum Pathol       Date:  2009-01       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.